Journal of pain and symptom management
-
J Pain Symptom Manage · Jan 2024
Randomized Controlled TrialImpact of Dosing and Duration of Dexamethasone on Serious Corticosteroid-Related Adverse Events.
Corticosteroids are commonly prescribed in oncology, but few studies have examined its adverse events (AEs) compared to placebo control. ⋯ Greater dexamethasone exposure, even at moderate doses, was associated with more serious AEs. Prescribers should cautiously weigh the risks and benefits of dexamethasone use, especially when considering for palliation of symptoms.
-
J Pain Symptom Manage · Jan 2024
Multicenter StudyCancer Pain Management in Patients Receiving Inpatient Specialized Palliative Care Services.
Cancer pain is a common complication that is frequently undertreated in patients with cancer. ⋯ SPC achieved cancer pain management over a short period with a high level of patient satisfaction resulting in significant pain reduction and few documented adverse events.
-
J Pain Symptom Manage · Jan 2024
ReviewMultilevel Determinants of Palliative Care Referral in Women with Advanced Ovarian Cancer: A Scoping Review.
Receipt of palliative care (PC) has long been suggested in practice for patients with advanced cancer for improved quality of life, mood, and prolonged survival. However, PC referrals in women with ovarian cancer remain suboptimal. ⋯ Various factors in the socioecological framework suggest that the decision for PC referral could be multifactorial and influenced by factors beyond the medical condition and status. Future research should aim to understand the impact of various socioecological factors on PC referral and examine PC referral experiences from the patient's perspective.
-
J Pain Symptom Manage · Jan 2024
Comparative StudyComparison of the effects of OPRM1 A118G polymorphism using different opioids: A prospective study.
μ-opioid receptor gene (OPRM1) A118G polymorphism (rs1799971) causes loss of N-glycosylation sites at the extracellular domain of μ-opioid receptors. G-allele carriers show a limited response to morphine; however, studies investigating the impact of A118G polymorphism on the efficacy of opioids other than morphine are limited. ⋯ Tapentadol and methadone may be more suitable than hydromorphone, oxycodone, and fentanyl for G-allele carriers due to their dual mechanism of action and low susceptibility to OPRM1 A118G polymorphism.